'We will invest for innovating TB control strategies'

What are the key challenges associated with the availability of GeneXpert? The high-cost of GeneXpert could limit its uptake, so we need to bring the price down. It is still too expensive for widespread implementation in developing countries. But, at the same time, manufacturers in India and elsewhere have already shown interest in developing low-cost generic molecular tests that would be widely affordable for health systems globally. Researchers are also exploring other, improved molecular diagnostics as well as serology tests for TB that will be faster, more affordable and easier to use in the field, including eventually a point-of-care test.

What are the new programs in the pipeline? The foundation will continue to invest in the innovative delivery of existing TB control strategies and development of better tools to prevent and treat the disease. We hope that, once ready, these innovations can be implemented on a wide scale to save more lives.